医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Qilu Pharmaceutical and ABEC Continue Large-Scale Bioreactor Partnership

2020年11月12日 PM11:21
このエントリーをはてなブックマークに追加


 

BETHLEHEM, Pa.

ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced Qilu Pharmaceutical Co. has again selected ABEC to rapidly expand production capacity at their cGMP manufacturing facility in Jinan, Shandong, China. ABEC is delivering several sets of large-scale, stainless-steel, cell-culture bioreactors. ABEC’s large-scale bioreactors previously installed at Qilu are currently the largest in operation in China.

To support a robust monoclonal antibody product pipeline, Qilu currently operates the largest total bioreactor capacity in China, and this expansion builds on that leadership. The new bioreactor trains will be installed at Qilu’s Biopharmaceutical Industrial Park, which is one of the largest biopharmaceutical industrial parks in China. Since 2009, Qilu has continuously chosen to partner with ABEC based on excellent process performance, consistent adherence to schedule, and long-term service and support. ABEC’s experience in large-scale bioreactor engineering, design, and manufacturing dates to the early 1990’s and is unmatched in the industry. This experience, coupled with continued investment in industry-leading capacity, ensures that Qilu’s aggressive productivity and time to market needs are met.

“As a leading multinational pharmaceutical company in China, Qilu is committed to bringing high-quality products to patients around the world,” said Yan Li, CEO, Qilu Pharmaceutical, Co. “ABEC’s continued support enables us to further develop our world-class cGMP production facilities.”

“We are honored to continue our long-term partnership with Qilu Pharmaceutical,” said Scott Pickering, ABEC President and CEO. “Qilu is a biopharmaceutical market leader, and we are proud to have contributed to their success for over 10 years.”

About ABEC

Since 1974, ABEC has been a global leader in delivering integrated process solutions and services for manufacturing in the biopharmaceutical industry. The majority of the world’s pharmaceutical and biotech companies are ABEC customers; with many of today’s leading therapies manufactured by processes and equipment engineered, manufactured, installed, and serviced by ABEC. ABEC’s unique value is based on long experience, complete in-house capabilities, a custom, flexible approach, and long-term credibility. Whether adding capacity or improving existing facilities, ABEC’s turn-key solutions and support services reduce overall cost and time to market while delivering maximum productivity. Visit abec.com, email info@abec.com, follow ABEC on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005682/en/

CONTACT

Media Contact:

Susan Cooper-Curcio

Director of Marketing

+1 (610) 861 4666, scurcio@abec.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 2021年嵌入式安全和安保峰会公布线上大会演讲者阵容
  • 組み込み技術安全&セキュリティーサミット(ESSS)2021が仮想カンファレンスの講演者の顔ぶれを公表
  • 武田薬品工業:2020年度は力強い利益率と強固なキャッシュ・フローとともに安定的な業績を達成、2021年度には実質的な売上収益成長のさらなる加速を見込
  • Takeda Delivers Resilient FY2020 Results With Strong Margins & Robust Cashflow; Underlying Revenue Growth Expected to Accelerate in FY2021
  • UPL Announces Collaboration With Meiji for Exclusive Access to Flupyrimin Rice in Southeast Asia